JAK3 inhibitors, in particular, have been demonstrated to decrease the production of pro-inflammatory cytokines, such as IL-2, IL-6 and IL-17, all of which contribute to the pathophysiology of rheumatoid arthritis. Here, JAK3 is linked to rheumatoid arthritis.